37 results about "DNA Microarray Chip" patented technology

The invention relates to information security technology, in particular to a virtual genome-based cryptosystem (VGC). The cryptosystem is provided with two matched keys, of which one is a virtual genome database (VGDB) consisting of random deoxyribonucleic acid (DNA) sequences and the other one is a position table that virtual genes of the VGDB are randomly distributed in a two-dimensional microarray, namely a virtual DNA microarray chip (VDMC). Any plaintext information can be freely written on the VDMC, namely points for forming the plaintext information are selected from the VDMC microarray. The selected points correspond to the virtual genes in the VGDB; small segments of DNA sequences are randomly selected from the virtual genes; and the uniqueness of the small segments of DNA sequences in the VGDB is determined by using a common tool of the bioinformatics, namely a basic local alignment search tool (BLAST), or other character string search algorithms such as a Knuth-Morris-Pratt (KMP) algorithm and the like. A cipher text is combined by the small segments of DNA sequences. The small segments of DNA sequences need only to perform BLAST on the VGDB during decryption, namely the points for forming the plaintext information can be discovered, and the plaintext information can be restored according to the VDMC. Any non-VGDB sequence can be randomly inserted into the cipher text and does not have any influence on the encryption. Thus, the VGC is an excellent information hiding system. In addition, the VGC key can be updated automatically so as to realize an indecipherable one-time-pad system. The cryptosystem is used for real-time quick secret information communication, digital signature and identity authentication.

The present invention relates to a screening method using the genes related to teratogenicity, more precisely the genes up- or down-regulated by a drug inducing teratogenicity such as thalidomide, valproic acid, and methotrexate and a method for screening of thalidomide, valproic acid and methotrexate using the genes. The genes of the present invention is based on reactive genes selected by DNA microarray chip, so that it is very effective in risk assessment and monitoring drugs or chemicals having high risk of teratogenicity and at the same time it can be used as a tool to examine mechanism of teratogenicity.

The invention relates to a gene mutation detection kit for the GS (Gilbert syndrome) and belongs to the technical field of biology. The kit comprises DNA (deoxyribose nucleic acid) micro-array chips formed by fixing an acrylamide modified PCR (polymerase chain reaction) product and other components on a propylene group modified slide as well as 6 nucleotide probe parts. The kit adopts a DNA micro-array technology, is simple and convenient to operate, low in price and capable of being applied to screening and clinical auxiliary diagnosis of diseases related to the GS caused by gene mutation.

The invention relates to a DNA microarray chip, in particular to an integrated high-flux detection DNA microarray chip for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1). A solid-phase carrier substrate is used, and an oligonucleotide probe is designed in view of genes of HBV, HCV and HIV-1 so as to prepare the DNA microarray chip; and when matched witha PCR primer and other components, the DNA microarray chip can simultaneously detect the three viruses in a plurality of samples with high sensitivity and high specificity. The DNA microarray chip ismainly used for screening the virus nucleic acid in blood and blood products.

The invention relates to a gene detecting kit used for clinical detection, in particular to the kit which adopts a DNA micro-array chip and a dual-temperature hybridization probe to execute the detection and typing on human leukocyte antigen gene in a high-throughput, high-efficiency and high-specificity manner and the usage thereof.

The invention discloses a DNA microarray chip, its detection method and its application in detecting CYP3A4, CYP3A5 and MDR1 gene polymorphisms. The chip includes a solid phase carrier and a probe, and the nucleotide sequence of the probe is as the probe The nucleotide sequences are shown in SEQ ID NO: 1 to SEQ ID NO: 49. The present invention first loads the probe on the solid phase carrier, then labels and prepares the target nucleotide sequence of the sample to be tested, then hybridizes the target nucleotide sequence with the probe on the chip, and finally analyzes the hybridization result The detection can obtain the information of CYP3A4, CYP3A5 and MDR1 genes in the sample to be tested. The chip of the present invention can simultaneously detect multiple genes on multiple samples at one time, with simple operation and high accuracy of results, and a large amount of genetic information of patients can be obtained through one detection, which can be used to guide the formulation of rational drug regimens and realize individualization medical.